ChemBioNet: Chemical Biology supported by Networks of Chemists and Biologists. Affinity Proteomics Meeting Alpbach. Michael Lisurek 15.3.

Similar documents
Introduction. OntoChem

Advanced Medicinal Chemistry SLIDES B

Using AutoDock for Virtual Screening

Dispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses

Introduction to Chemoinformatics and Drug Discovery

Receptor Based Drug Design (1)

Drug Informatics for Chemical Genomics...

Data Quality Issues That Can Impact Drug Discovery

Supporting Information (Part II) for ACS Combinatorial Science

Navigation in Chemical Space Towards Biological Activity. Peter Ertl Novartis Institutes for BioMedical Research Basel, Switzerland

Structural biology and drug design: An overview

FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC )

KNIME-based scoring functions in Muse 3.0. KNIME User Group Meeting 2013 Fabian Bös

Using Bayesian Statistics to Predict Water Affinity and Behavior in Protein Binding Sites. J. Andrew Surface

Virtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME

Chemical library design

György M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences

AMRI COMPOUND LIBRARY CONSORTIUM: A NOVEL WAY TO FILL YOUR DRUG PIPELINE

COMBINATORIAL CHEMISTRY: CURRENT APPROACH

Dr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre

In silico pharmacology for drug discovery

Zoe Blaxill Analytical Sciences Discovery Research. High Frequency Acoustic Technology: Evaluation for Compound Mixing and Dissolution in HTS.

Enamine Golden Fragment Library

Introduction to FBDD Fragment screening methods and library design

Cheminformatics Role in Pharmaceutical Industry. Randal Chen Ph.D. Abbott Laboratories Aug. 23, 2004 ACS

BioSolveIT. A Combinatorial Approach for Handling of Protonation and Tautomer Ambiguities in Docking Experiments

Computational Methods and Drug-Likeness. Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004

User Guide for LeDock

Relative Drug Likelihood: Going beyond Drug-Likeness

October 6 University Faculty of pharmacy Computer Aided Drug Design Unit

NMR-spectroscopic investigation. of proteins in solution

EMPIRICAL VS. RATIONAL METHODS OF DISCOVERING NEW DRUGS

Retrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a

Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining

Plan. Day 2: Exercise on MHC molecules.

Unlocking the potential of your drug discovery programme

Combinatorial Heterogeneous Catalysis

ASSESSING THE DRUG ABILITY OF CHALCONES USING IN- SILICO TOOLS

DivCalc: A Utility for Diversity Analysis and Compound Sampling

Easier and Better Exploitation of PhysChem Properties in Medicinal Chemistry

Chemogenomic: Approaches to Rational Drug Design. Jonas Skjødt Møller

Automated Compound Collection Enhancement: how Pipeline Pilot preserved our sanity. Darren Green GSK

Richik N. Ghosh, Linnette Grove, and Oleg Lapets ASSAY and Drug Development Technologies 2004, 2:

COMPUTER AIDED DRUG DESIGN (CADD) AND DEVELOPMENT METHODS

Building innovative drug discovery alliances. Just in KNIME: Successful Process Driven Drug Discovery

Synthetic organic compounds

Plan. Lecture: What is Chemoinformatics and Drug Design? Description of Support Vector Machine (SVM) and its used in Chemoinformatics.

Design and Synthesis of the Comprehensive Fragment Library

COMBINATORIAL CHEMISTRY IN A HISTORICAL PERSPECTIVE

Welcome to Week 5. Chapter 9 - Binding, Structure, and Diversity. 9.1 Intermolecular Forces. Starting week five video. Introduction to Chapter 9

Early Stages of Drug Discovery in the Pharmaceutical Industry

Computational Chemistry in Drug Design. Xavier Fradera Barcelona, 17/4/2007

Next Generation Computational Chemistry Tools to Predict Toxicity of CWAs

Synthetic organic compounds

In Silico Investigation of Off-Target Effects

Navigating between patents, papers, abstracts and databases using public sources and tools

Applications Note 215 September 2009

Application Note. Authors. Introduction. Lauren E. Frick and William A. LaMarr Agilent Technologies, Inc. Wakefield, MA, USA

Supplementary Information. Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity across Chemical Libraries

Protein Structure Determination using NMR Spectroscopy. Cesar Trinidad

Biologically Relevant Molecular Comparisons. Mark Mackey

Characterization of Reversible Kinase Inhibitors using Microfluidic Mobility-Shift Assays

QSAR/QSPR modeling. Quantitative Structure-Activity Relationships Quantitative Structure-Property-Relationships

Chemical Data Retrieval and Management

Web tools for Monomer selection, Library Design and Compound Acquisition. Andrew Leach GlaxoSmithKline Research and Development Stevenage

High-throughput Quantification of DNA for NGS Library Prep with the Zephyr G3 Workstation and the VICTOR Nivo Plate Reader

mrna proteins DNA predicts certain possible future health issues Limited info concerning evolving health; advanced measurement technologies

An Integrated Approach to in-silico

Virtual screening in drug discovery

Hit Finding and Optimization Using BLAZE & FORGE

Ignasi Belda, PhD CEO. HPC Advisory Council Spain Conference 2015

ChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD)

Problem Set 5 Question 1

Analysis of a Large Structure/Biological Activity. Data Set Using Recursive Partitioning and. Simulated Annealing

Study of Non-Covalent Complexes by ESI-MS. By Quinn Tays

Expanding the scope of literature data with document to structure tools PatentInformatics applications at Aptuit

A Picture Paints a Thousand Words Visualisation of SAR. John Cumming, AstraZeneca, Alderley Park, UK

bcl::cheminfo Suite Enables Machine Learning-Based Drug Discovery Using GPUs Edward W. Lowe, Jr. Nils Woetzel May 17, 2012

Kinome-wide Activity Models from Diverse High-Quality Datasets

CHAPTER 6 QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP (QSAR) ANALYSIS

Medicinal Chemistry and Chemical Biology

Introduction to Chemoinformatics

The Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL

Institute of Organic Chemistry with Centre of Phytochemistry Bulgarian Academy of Sciences

Alkane/water partition coefficients and hydrogen bonding. Peter Kenny

Using the FL600 Fluorescence Microplate Reader for Chemiluminescence Detection What s a lumin anyway?

Supporting Information

Bioengineering & Bioinformatics Summer Institute, Dept. Computational Biology, University of Pittsburgh, PGH, PA

QSAR Modeling of ErbB1 Inhibitors Using Genetic Algorithm-Based Regression

Fragment based drug discovery in teams of medicinal and computational chemists. Carsten Detering

has its own advantages and drawbacks, depending on the questions facing the drug discovery.

FRAUNHOFER IME SCREENINGPORT

ADVANCED ANALYTICAL LABORATORY

Capturing Chemistry. What you see is what you get In the world of mechanism and chemical transformations

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

CHEMISTRY (CHE) CHE 104 General Descriptive Chemistry II 3

The use of Design of Experiments to develop Efficient Arrays for SAR and Property Exploration

Contents 1 Open-Source Tools, Techniques, and Data in Chemoinformatics

Solved and Unsolved Problems in Chemoinformatics

Use of data mining and chemoinformatics in the identification and optimization of high-throughput screening hits for NTDs

Transcription:

ChemBioet: Chemical Biology supported by etworks of Chemists and Biologists Affinity Proteomics Meeting Alpbach Michael Lisurek 15.3.2007

- Introduction - Equipment Screening Unit - Screening Compound Collection - Screening Project

Status of Usage of HTS Pharmaceutical Companies: - Standard Tool for Drug Development since Decades! Academic Institutions: - Lack of Available Compound Libraries - Lack of Automation and Know-How - Lack of Supporting Chemical Synthesis Resources - Lack of Support by Computational Drug Design

Medicinal Chemistry/ Molecular Modeling Automated Screening Unique Technology nline Database Screening Unit Compound Library Mobility Shift on Chips HT Cellular Imaging

ChemBioet: Academic Screening etwork Chemistry Compounds meets Biology Assays & Targets Bioprofiles Screening Units Compound Libraries & Technological Know-How for HTS Molecular Probes Combined Database in silico Methods

Equipment Screening Unit Supporting Academic Projects

Liquid Handling Robot for Library Transfer 384 Well Dispenser 384 Well Washer MTP Speed-Vac

Automated Mobility Shift Screening (LabChip-250) Caliper Life Sciences Leibniz-Institut für Molekulare Pharmakologie Boston - Berlin

Automated Mobility Shift Screening (LabChip-250) Caliper Life Sciences, Screening Technology

Reader-Equipment Safire 2 Genios Pro - Absorption Scans (Continuous Wavelength Range) - Fluorescence Intensity - Luminescence - Fluorescence Polarization - Luminescence and Chemiluminescence - Luciferase Assays - Realtime Kinetics

Automated Microscope : Automated Cell Culture and Sample Preparation Automated Image Analysis Software: - Drugs affecting Proliferation of Tumor Cells (Microtubuli) - euroregeneration (Differentiation of euronal Cells) - Translocations (Inflammation, Leukemia)

Automated Image Recognition: Inflammation Inactive Leibniz-Institut für Molekulare Pharmakologie Active Picture- Documents Multiparameter- Spreadsheets Cell nucleus: 20.63 524.09 Cytoplasm: 141.46 45.95

Screening Compound Collection Strategy for the Assembly of a Screening Compound Collection

Assembly of a Screening Compound Collection Enriched with Bioactive Scaffolds > 2.000.000 Lowest Estimate of Stable Drug Candidates: 10 13 1 Million Tests / Day 27 300 Years ~ 17.000 (< 1 %) Rational Pre-selection of Bioactive & Chemically Diverse Compounds for ChemBioet

Assembly of a Screening Compound Collection Enriched with Bioactive Scaffolds > 2.000.000 Lowest Estimate of Stable Drug Candidates: 10 13 1 Million Tests / Day 27 300 Years ~ 17.000 (< 1 %) Rational Pre-selection of Bioactive & Chemically Diverse Compounds for ChemBioet

Strategy for the Assembly of a Screening Compound Collection 1 st Step: Removing reactive, unstable and irrelevant Compounds S Hal 2 nd Step: Search for Compounds containing bioactive Substructures, derived from the WDI Hal S S Hal H C C 3 rd Step: Selection of a calculated Diverse Subset C CH 2 I Se 4 th Step: Lipinskis Rule of 5 Self-made Filter / Sybyl (Tripos)

1 st Step: Removing reactive, unstable and irrelevant Compounds S 2 nd Step: Search for Compounds containing bioactive Substructures, derived from the WDI S 3 rd Step: Selection of a calculated Diverse Subset 4 th Step: Lipinskis Rule of 5 Self-made Filter / Sybyl (Tripos)

1 st Step: Removing reactive, unstable and irrelevant Compounds Br Br Br 2 nd Step: Search for Compounds containing bioactive Substructures, derived from the WDI S H F Br S H 3 rd Step: Selection of a calculated Diverse Subset H H H 4 th Step: Lipinskis Rule of 5

1 st Step: Removing reactive, unstable and irrelevant Compounds Br Br Br 2 nd Step: Search for Compounds containing bioactive Substructures, derived from the WDI S H F Br S H 3 rd Step: Selection of a calculated Diverse Subset H H H 4 th Step: Lipinskis Rule of 5

1 st Step: Removing reactive, unstable and irrelevant Compounds Br Br Br 2 nd Step: Search for Compounds containing bioactive Substructures, derived from the WDI S H F Br S H 3 rd Step: Selection of a calculated Diverse Subset H H H 4 th Step: Lipinskis Rule of 5 Diverse Subset Tool / ME (CCG) MW, H ACC, H D,,, RT, Substructures, logp, logs, logd

1 st Step: Removing reactive, unstable and irrelevant Compounds 2 nd Step: Search for Compounds containing bioactive Substructures, derived from the WDI 3 rd Step: Selection of a calculated Diverse Subset 4 th Step: Lipinskis Rule of 5 C. Lipinski et al. (1997) Adv. Drug Del. Rev. 23, 3-25 H-Bond Donors < 5 H-Bond Acceptors <10 LogP < 5 MW < 500 (< 800) Compute Descriptors / ME (CCG)

Where are the Bioactive Substructures derived from? World Drug Index (WDI): Database of 35 000 Biologically Active Small Molecules Search for Maximum Common Substructures: ClassPharmer (BioReason)

Where are the Bioactive Substructures derived from? World Drug Index (WDI): Database of 35 000 Biologically Active Small Molecules Search for Maximum Common Substructures: ClassPharmer (BioReason) CH CH 2 S CH

Where are the Bioactive Substructures derived from? World Drug Index (WDI): Database of 35 000 Biologically Active Small Molecules Search for Maximum Common Substructures: ClassPharmer (BioReason) CH CH 2 S CH 573 Maximum Common Substructures

Screening Projects Recent Successful Example

M. tuberculosis Myo-Inositol-Phosphatase Antagonists Primary Screen: 100 µm Compound Substrate: Sorbitol-6-Phosphate Detection: P i -Malachitegreen-Mo Complex o Inhibition Blank ovel Antagonists with K i < 1 µm Phosphate Reference 500 µm 400 µm 300 µm 200 µm 100 µm 50 µm 0 µm

ovel Small Molecule Antagonist of M. tuberculosis Growth Inhibition in Medium A C* 200 100 50 10 200 100 50 10 µm B Medium only Tb only Growth Inhibition in Macrophages CFU/ml 1.0 10 07 -C 8.0 10 06 6.0 10 06 4.0 10 06 2.0 10 06 1 2 3 4 5 + C Day

FMP: - Med. Chem.: J. Rademann R. Raz M. Schmidt S. Al-Gharabli - Drug Design: R. Kühne - MR: H. schkinat S. Hübel - Screening Unit: J.P. von Kries C. Erdmann S. Behnken V. Pütter M. Schade MDC: K. Hellmuth W. Birchmeier. Rötzschke K. Falk C. Scheidereit E. Wanker M. Lipp MPI, Dortmund: H. Prinz, A. ören H. Waldmann (*HWA) www.chembionet.de Structural Genomics Consortium EMBL-Hamburg: M. Wilmanns M. Weiss P. Tucker MPG-Hamburg: H. Bartunik MPI-IB, Berlin S. Kaufmann SGC M. Sundström S. Knapp University of xford